JCOG0509_2B | R Documentation |
Kaplan-Meier digitized data from JCOG0509, figure 2B (PMID 24638015). A reported sample size of 284 for a primary endpoint of OS in lung cancer.
JCOG0509_2B
A data frame of 284 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (amrubicin_cisplatin, irinotecan_cisplatin) | |
Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol 2014; 32: 1262–8.
summary(JCOG0509_2B)
kmplot(JCOG0509_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.